Janux Therapeutics, Inc. Financing Cash Flow
Janux Therapeutics, Inc. (JANX) reported Financing Cash Flow of $5.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Janux Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.24M, a 134.80% increase year-over-year.
- Janux Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $3.54M, a 539.89% increase year-over-year.
- Janux Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.94M, a 99.24% decline year-over-year.
- Janux Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $493.00K, a 70.10% decline year-over-year.
- Janux Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $4.95M, a 99.31% decline from fiscal 2024.
- Janux Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $713.24M, a 1097.75% increase from fiscal 2023.
- Janux Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $59.55M, a 11809.60% increase from fiscal 2022.
- Janux Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $500.00K, a 99.87% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.79M 10-Q · filed 2026-08-06 | $8.73M derived: sum of 3 quarters · filed 2026-08-06 | $9.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.54M 10-Q · filed 2026-05-07 | $6.49M derived: sum of 2 quarters · filed 2026-05-07 | $6.98M derived: sum of 3 quarters · filed 2026-05-07 | $7.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.44M derived: sum of 2 quarters · filed 2026-02-26 | $4.39M derived: sum of 3 quarters · filed 2026-08-06 | $4.95M 10-K · filed 2026-02-26 |
| 2025-09-30 | $493.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.45M derived: sum of 2 quarters · filed 2026-08-06 | $2.00M 10-Q · filed 2025-11-06 | $388.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $954.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.51M 10-Q · filed 2026-08-06 | $388.16M derived: sum of 3 quarters · filed 2026-08-06 | $389.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $554.00K 10-Q · filed 2026-05-07 | $387.20M derived: sum of 2 quarters · filed 2026-05-07 | $388.85M derived: sum of 3 quarters · filed 2026-05-07 | $391.62M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $386.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $388.30M derived: sum of 2 quarters · filed 2026-02-26 | $391.06M derived: sum of 3 quarters · filed 2026-02-26 | $713.24M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.41M derived: sum of 2 quarters · filed 2025-11-06 | $326.58M 10-Q · filed 2025-11-06 | $327.42M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $324.94M 10-Q · filed 2025-08-07 | $325.77M derived: sum of 3 quarters · filed 2026-02-26 | $382.38M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $322.17M 10-Q · filed 2025-05-08 | $323.00M derived: sum of 2 quarters · filed 2026-02-26 | $379.61M derived: sum of 3 quarters · filed 2026-02-26 | $380.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $831.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $57.44M derived: sum of 2 quarters · filed 2026-02-26 | $57.97M derived: sum of 3 quarters · filed 2026-02-26 | $59.55M 10-K · filed 2026-02-26 |
| 2023-09-30 | $56.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $57.14M derived: sum of 2 quarters · filed 2024-11-06 | $58.72M 10-Q · filed 2024-11-06 | $58.91M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $528.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $2.11M 10-Q · filed 2024-08-07 | $2.30M derived: sum of 3 quarters · filed 2025-02-27 | $2.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.58M 10-Q · filed 2024-05-08 | $1.77M derived: sum of 2 quarters · filed 2025-02-27 | $1.77M derived: sum of 3 quarters · filed 2025-02-27 | $2.08M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $191.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $191.00K derived: sum of 2 quarters · filed 2025-02-27 | $499.00K derived: sum of 3 quarters · filed 2025-02-27 | $500.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $308.00K derived: sum of 2 quarters · filed 2023-11-07 | $309.00K 10-Q · filed 2023-11-07 | $473.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $308.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $309.00K 10-Q · filed 2023-08-08 | $473.00K derived: sum of 3 quarters · filed 2023-08-08 | -$370.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.00K 10-Q · filed 2023-05-09 | $165.00K derived: sum of 2 quarters · filed 2023-05-09 | -$678.00K derived: sum of 3 quarters · filed 2023-05-09 | $328.98M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $164.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$679.00K derived: sum of 2 quarters · filed 2023-03-10 | $328.98M derived: sum of 3 quarters · filed 2023-03-10 | $386.52M 10-K · filed 2023-03-10 |
| 2021-09-30 | -$843.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $328.81M derived: sum of 2 quarters · filed 2022-11-10 | $386.36M 10-Q · filed 2022-11-10 | $390.91M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $329.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $387.20M 10-Q · filed 2022-08-09 | $391.76M derived: sum of 3 quarters · filed 2022-08-09 | $391.72M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $57.55M 10-Q · filed 2022-05-10 | $62.10M derived: sum of 2 quarters · filed 2022-05-10 | $62.07M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $4.52M derived: sum of 2 quarters · filed 2022-03-18 | $11.52M 10-K · filed 2022-03-18 | |
| 2020-09-30 | -$33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $6.97M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $7.00M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |